Completion of the impurity profile of lymecycline: Formal identification of impurities E and F
Stéphan Billié1, Kevin Reversé2, Sandrine Chambon2
1Galderma SA, Av. d'Ouchy 4, 1006 Lausanne, Switzerland.
Journal of Pharmaceutical and Biomedical Analysis
|August 25, 2022
Abstract:
Lymecycline is the drug substance (DS) used in the Galderma drug product Tetralysal® capsules with 7 impurities currently described in the pharmacopeia labelled as A-G. In the current monograph, the structural identity of all impurities except E and F have been formally identified. In this manuscript, through both formal synthesis and preparative chromatography, we are the first group to confirm the structural identity, response factor of Impurity F and conditions which exacerbate the formation of both impurities.
Keywords:
4-desmethylaminotetracyclineC5a-5 dehydro-tetracyclineLymecyclinePolonovski reactionThermal degradation

